© 2000 by Oxford University Press
Journal of the National Cancer Institute, Vol. 92, No. 11, 912-917,
June 7, 2000
© 2000 Oxford University Press
Influence of Cellular Ganglioside Depletion on Tumor Formation
Affiliations of authors: Glycobiology Program, Center for Cancer and Transplantation Biology, Children's Research Institute, Washington, DC, and Departments of Pediatrics and Biochemistry/Molecular Biology, The George Washington University School of Medicine, Washington, DC.
Correspondence to: Stephan Ladisch, M.D., Center for Cancer and Transplantation Biology, Children's Research Institute, 111 Michigan Ave., N.W., Washington, DC 20010 (e-mail: SLadisch{at}cnmc.org).
Background: Gangliosides are immunosuppressive cell surface molecules that are often present in high concentrations in and shed actively by tumor cells. These molecules inhibit the antitumor immune response that is implicated in tumor rejection. We therefore determined the ability of tumor cells pharmacologically depleted of gangliosides to form tumors in mice. Methods: We tested a ganglioside-rich subline of B16 murine melanoma, MEB4, and MEB4 cells that had been depleted of endogenous gangliosides by incubation with 0.5 µM 1-phenyl-2-hexadecanoylamino-3-pyrrolidino-1-propanol, a specific inhibitor of the enzyme glucosylceramide synthase. Tumor formation was assessed twice a week for 10 weeks after the intradermal injection of tumor cells, and metastatic potential was assessed 4 weeks after tail vein injection of tumor cells. All P values are from two-sided tests. Results: Reduction of the ganglioside content of MEB4 cells, which was not cytotoxic to cells and did not inhibit cell proliferation in vitro, markedly reduced their ability to form tumors. Only 40% of the mice given an intradermal injection of 105 ganglioside-depleted MEB4 cells developed tumors compared with 100% of the mice given an injection of 105 control MEB4 cells (P<.001). Ganglioside depletion also reduced metastasis: A mean of five pulmonary metastases was detected per mouse given an injection of 2 x 105 ganglioside-depleted MEB4 cells compared with a mean of 25 per mouse given an injection of 2 x 105 control MEB4 cells. Conclusion: Tumor cells with a pharmacologically decreased concentration of gangliosides produce fewer tumors in mice than do untreated cells, suggesting that pharmacologic depletion of gangliosides should be explored further as a therapeutic approach to cancer.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. Mukherjee, A. C. Faber, L. M. Shelton, R. C. Baek, T. C. Chiles, and T. N. Seyfried Thematic Review Series: Sphingolipids. Ganglioside GM3 suppresses the proangiogenic effects of vascular endothelial growth factor and ganglioside GD1a J. Lipid Res., May 1, 2008; 49(5): 929 - 938. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Das, G. Sa, C. Hilston, D. Kudo, P. Rayman, K. Biswas, L. Molto, R. Bukowski, B. Rini, J. H. Finke, et al. GM1 and Tumor Necrosis Factor-{alpha}, Overexpressed in Renal Cell Carcinoma, Synergize to Induce T-Cell Apoptosis Cancer Res., March 15, 2008; 68(6): 2014 - 2023. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Liu, J. McCarthy, and S. Ladisch Membrane Ganglioside Enrichment Lowers the Threshold for Vascular Endothelial Cell Angiogenic Signaling Cancer Res., November 1, 2006; 66(21): 10408 - 10414. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. A. Crespo, X. Sun, J. G. Cripps, and R. Fernandez-Botran The immunoregulatory effects of gangliosides involve immune deviation favoring type-2 T cell responses J. Leukoc. Biol., March 1, 2006; 79(3): 586 - 595. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Chahlavi, P. Rayman, A. L. Richmond, K. Biswas, R. Zhang, M. Vogelbaum, C. Tannenbaum, G. Barnett, and J. H. Finke Glioblastomas Induce T-Lymphocyte Death by Two Distinct Pathways Involving Gangliosides and CD70 Cancer Res., June 15, 2005; 65(12): 5428 - 5438. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-Y. Liu, T. Y. Han, J. Y. Yu, A. Bitterman, A. Le, A. E. Giuliano, and M. C. Cabot Oligonucleotides blocking glucosylceramide synthase expression selectively reverse drug resistance in cancer cells J. Lipid Res., May 1, 2004; 45(5): 933 - 940. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. V. Thornton, D. Kudo, P. Rayman, C. Horton, L. Molto, M. K. Cathcart, C. Ng, E. Paszkiewicz-Kozik, R. Bukowski, I. Derweesh, et al. Degradation of NF-{kappa}B in T Cells by Gangliosides Expressed on Renal Cell Carcinomas J. Immunol., March 15, 2004; 172(6): 3480 - 3490. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Ishitsuka, A. Yamaji-Hasegawa, A. Makino, Y. Hirabayashi, and T. Kobayashi A Lipid-Specific Toxin Reveals Heterogeneity of Sphingomyelin-Containing Membranes Biophys. J., January 1, 2004; 86(1): 296 - 307. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Saito, H. Aoki, A. Ito, S. Ueno, T. Wada, K. Mitsuzuka, M. Satoh, Y. Arai, and T. Miyagi Human {alpha}2,3-Sialyltransferase (ST3Gal II) Is a Stage-specific Embryonic Antigen-4 Synthase J. Biol. Chem., July 11, 2003; 278(29): 26474 - 26479. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Weiss, S. Hettmer, P. Smith, and S. Ladisch Inhibition of Melanoma Tumor Growth by a Novel Inhibitor of Glucosylceramide Synthase Cancer Res., July 1, 2003; 63(13): 3654 - 3658. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Kudo, P. Rayman, C. Horton, M. K. Cathcart, R. M. Bukowski, M. Thornton, C. Tannenbaum, and J. H. Finke Gangliosides Expressed by the Renal Cell Carcinoma Cell Line SK-RC-45 Are Involved in Tumor-induced Apoptosis of T Cells Cancer Res., April 1, 2003; 63(7): 1676 - 1683. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Peguet-Navarro, M. Sportouch, I. Popa, O. Berthier, D. Schmitt, and J. Portoukalian Gangliosides from Human Melanoma Tumors Impair Dendritic Cell Differentiation from Monocytes and Induce Their Apoptosis J. Immunol., April 1, 2003; 170(7): 3488 - 3494. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Sriram, S. Cho, P. Li, P. W. O'Donnell, C. Dunn, K. Hayakawa, J. S. Blum, and R. R. Brutkiewicz Inhibition of glycolipid shedding rescues recognition of a CD1+ T cell lymphoma by natural killer T (NKT) cells PNAS, June 11, 2002; 99(12): 8197 - 8202. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Deng, R. Li, M. Guerrera, Y. Liu, and S. Ladisch Transfection of glucosylceramide synthase antisense inhibits mouse melanoma formation Glycobiology, March 1, 2002; 12(3): 145 - 152. [Abstract] [Full Text] [PDF]
|
|